RESOURCES

Explore resources from the 340B Advocacy Initiative and others.

Senators Agree: 340B Is Broken and Must Be Reformed

October 29, 2025

An October hearing held by the U.S. Senate HELP Committee delivered bipartisan calls for both preservation and reform. At first glance, those two goals may seem at odds with each other. But when it comes to 340B, reform may be what’s needed to preserve the program for the future.

Momentum Builds for 340B Reform with New Congressional Focus

July 23, 2026

U.S. Senator Bill Cassidy (R-La.), Chairman of the Senate HELP Committee, recently released a legislative discussion draft for the 340B Drug Pricing Integrity and Affordability for Patients Act, aiming to overhaul the program. Shortly after, Representatives Scott Peters (D-CA) and Dr. John Joyce (R-PA) introduced the bipartisan SECURE 340B Act in the House.

How 340B Incentivizes Health Care Consolidation

September 21, 2026

A patient walks into their oncologist's office for a routine follow-up: same doctor, same waiting room, same blood draw she's had for years. Then the bill arrives: four times what she paid last time for the same visit. One reason for the increase in hospital acquisition of independent practices is the federal 340B drug discount program available to qualifying hospitals.

A 340B Vendor Draws Scrutiny from U.S. Senate

March 11, 2026

A U.S. Senate investigation notes that Apexus appears to have expanded its business beyond its core role as a vendor, working with covered entities to increase 340B utilization and creating additional business lines to increase its own profits.

340B-Driven Health Care Consolidation Came to Iowa

October 21, 2026

In 2024, University of Iowa Health Care acquired Mission Cancer + Blood, moving roughly 20 oncology clinics from an independent practice into a 340B-covered hospital system. In 2025, UIHC shifted the clinics to hospital-based billing. Patient costs are rising for the same blood test, injection, with costs per visit rising from about $140 to more than $740.